Vaxess Technologies, Inc.


STEX25
Active dates:

April 13, 2020 - April 13, 2020
STEX25 Participation:
April 13, 2020 - July 9, 2021
Company information

c/o 790 Memorial Drive, Suite 200
Cambridge, MA 02139
United States

Elevator Pitch

Elevator Pitch

Vaxess Technologies is a venture-backed biotechnology company developing novel products based on its proprietary MIMIX microneedle delivery platform. Our lead program is a sustain-release flu microneedle patch. We also have a pipeline of undisclosed targets including mRNA, immun/ooncology and other in-house targets and in partnership with several pharmaceutical companies.
Description

Description

Vaxess Technologies is a venture-backed biotechnology company developing novel products based on its proprietary MIMIX microneedle delivery platform. Our lead program is a sustain-release flu microneedle patch. We also have a pipeline of undisclosed targets including mRNA, immun/ooncology and other in-house targets and in partnership with several pharmaceutical companies.

Vaxess is commercializing a proprietary technology that uses a silk-derived protein to stabilize vaccines so they can be stored and shipped without refrigeration. Vaxess strives to not only lower the cost of vaccine distribution, but also increase access to life-saving products for people around the world.

Proprietary Silk Protein Technology -- Fibroin, a protein found in native silk fibers, has unique properties that enable stabilization of biological compounds. Research & Development at Vaxess is cross-disciplinary, integrating aspects of chemistry, biology, immunology, biomedical and chemical engineering, and covers a wide range of product targets.
Technology Description

Technology Description

Vaxess is developing its proprietary MIMIX™ therapies based on technology originally developed at Tufts University and MIT. Vaxess is a venture-funded company that is also supported by the NIH and NSF.